Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group

Rita O Oladele, Iorhen E Akase, Ahmed H Fahal, Nelesh P Govender, Martin Hoenigl, Jean Pierre Gangneux, Tom M Chiller, David W Denning, Oliver A Cornely, Arunaloke Chakrabarti

To cite this version:
Rita O Oladele, Iorhen E Akase, Ahmed H Fahal, Nelesh P Govender, Martin Hoenigl, et al.. Bridging the knowledge gap on mycoses in Africa: Setting up a Pan-African Mycology Working Group. Mycoses, Wiley, 2020, 63 (3), pp.244-249. 10.1111/myc.13044. hal-02441218

HAL Id: hal-02441218
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02441218
Submitted on 12 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Bridging the knowledge gap on mycoses in Africa; setting up a Pan-African Mycology Working Group

Oladele RO¹, Akase IE², Fahal A³, Govender NP⁴, Honigl M⁵,⁶, Gangneux JP⁷, Chiller TM⁸, Denning DW⁹, Cornely OA¹⁰ and Chakrabarti A¹¹

¹ Department of Medical Microbiology & Parasitology, College of Medicine University of Lagos
² Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria
³ The Mycetoma Research Centre, Khartoum, Sudan
⁴ National Institute for Communicable Diseases, a Division of the National Health Laboratory Service and University of the Witwatersrand, Johannesburg, South Africa.
⁵ Division of Infectious Diseases and Global Public Health University of California San Diego, USA ⁶Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, Austria
7 CHU de Rennes, Univ Rennes, Inserm, Irset (Institut de recherche en santé, environnement et travail) - UMR_S, 1085, Rennes, France
8 Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
9 Global Action Fund for Fungal Infections, Geneva, Switzerland and the University of Manchester, Manchester, UK.
10 Department I of Internal Medicine, European Diamond Excellence Center of Medical Mycology, University Hospital Cologne; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); and Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
11 Department of Medical Microbiology, Postgraduate Institute of Medical Education & Research Chandigarh, India

Correspondence

Rita O. Oladele,

Department of Medical Microbiology & Parasitology, College of Medicine of University of Lagos,

Lagos, Nigeria.

Email: oladelerita@gmail.com

All authors contributed equally to the development of this manuscript

No Conflict of Interest
Abstract
Most African countries have poorly funded and overburdened health systems. Additionally, a high prevalence of HIV in Sub-Saharan Africa contributes to a high burden of opportunistic fungal infections. Data generated by GAFFI from 15 of 57 African countries revealed that an estimated 47 million Africans suffer from fungal diseases, of whom an estimated 1.7 million suffer from a serious fungal infection annually. Almost all African countries lack a surveillance system for fungal infections with the exception of South Africa. South Africa is also the only African country with a national mycology reference laboratory. Across the continent, there is a pervasive picture of inadequate/poor diagnostic capacity, low level of awareness among health care workers and policy makers as well as unavailability and non-accessibility to essential antifungal medications. Recent outreach efforts by the International Society for Human and Animal Mycology (ISHAM) and the European Confederation of Medical Mycology (ECMM) have aimed to increase involvement of African countries and experts in global initiatives such as “One World One Guideline” and also the ECMM Academy. Recently, under the auspices of ISHAM, the African sub-region created a network of mycology experts whose goal is organize and engage African leaders in the field of medical mycology. The aim of this ISHAM Working Group is to facilitate interaction and synergy among regional leaders in order to develop educational programs for capacity building to aid in the diagnosis and care of patients with fungal infections in Africa. The working group will also encourage country initiatives to develop clinical guidelines, to support surveys, and to support the establishment of reference mycology laboratories.
Introduction
Fungal pathogens are a growing threat globally. Over a billion people are directly affected by mycoses globally, 150 million of who have a serious or life threatening infection. More than 1.6 million people die of fungal diseases each year: ~500,000 of which are AIDS-related and 450,000 are thought to be due to chronic pulmonary aspergillosis. The African continent has an estimated population of 1.3 billion people accounting for roughly about a fifth of the world’s population and about 75% of all the 37 million human immunodeficiency virus (HIV) infected people. Approximately 50% fungal related deaths in the setting of HIV infections probably occur in Africa, although vital statistics are missing from most African countries. From the data generated by GAFFI (Global Action Funds for Fungal Infections); an estimated 47.6 million Africans suffer from fungal diseases, of which 1.7million suffer from a serious fungal infection annually. This is particularly alarming since these estimates are based on data from only 15 (of 57) African countries (table 1). Almost all African countries lack a surveillance system for fungal infections; the only exception is South Africa. Only South Africa has a national mycology reference laboratory.

Table 1: Estimated burden of fungal infections in Africa

Africa is endemic for histoplasmosis (including African histoplasmosis caused by *H. capsulatum var duboisii*), emergomycosis, mycetoma, chromoblastomycosis and several other endemic fungi. Among patients with HIV infection, cryptococcal meningitis and *Pneumocystis* pneumonia are a common cause of death among many African patients. Additionally, invasive candidiasis and aspergillosis and chronic pulmonary aspergillosis, fungal asthma, fungal keratitis and tinea infections all contribute to significant morbidity and mortality. A systematic review on fungal keratitis revealed an estimate of 13.5/100,000 annually in Africa. Certain fungal infections are peculiar to or more common among Africans (see Table 2) while others are rarely reported in Africa, including adiaspiromycosis, lobomycosis, blastomycosis and sporotrichosis. This may not necessarily be due to absence of the diseases but due to lack of diagnostic capacity.
Other endemic mycoses are not endemic in Africa and may be imported, including talaromycosis, coccidioidomycosis and paracoccidioidomycosis. Precise data on the true prevalence of fungal infections is unavailable in most parts in Africa, which is especially pronounced for African histoplasmosis and blastomycosis. In contrast, the epidemiology of mycetoma, cryptococcosis, emergomycosis and Candida auris has been better described in some areas. This is due to (1) extensive work that has been done and is still on-going by van de Sande and Fahal research teams (mycetoma in Sudan) which has led to the establishment of a WHO Collaborating Centre in Sudan; (2) The relationship of HIV/AIDS (sub-Saharan Africa bears a significant part of the burden globally) and cryptococcal meningitis; (3) the presence of a defined public health agenda, a mycology reference laboratory and national surveillance network in South Africa, which has aided Govender and other researchers to describe the epidemiology of emergomycosis, cryptococcal meningitis and candidaemia (caused by emerging azole-resistant pathogens such as Candida auris and Candida parapsilosis). The recent revolution in non-culture based diagnostics has yet to penetrate in Africa, with the one partial exception of cryptococcal antigen testing. For example, PCR for Pneumocystis was first described in 1991 was commercialised and standardised in 2011, but is not yet used diagnostically in Africa (except in South Africa), despite multiple studies showing its clinical value, especially in children. Many fungi cannot easily be grown under lab conditions (or plates get contaminated in non-air conditioned laboratories), and culturing is time consuming and requires specialist training; thus, there is a need for diagnostics that can be widely applied by laboratory technicians lacking traditional fungal identification skills and facilities.

Against the high burden of fungal infections in Africa, most African countries have poorly funded and overburdened health systems. Additionally, there is a pervasive picture of inadequate/ poor diagnostic capacity, low level of awareness among health care workers...
and policy makers, unavailability and non-accessibility of antifungal medications. Data from GAFFI website shows that among the 56 territories and countries in Africa, amphotericin B is not registered in 12 and unavailable in 25, fluconazole is not registered in 8 and unknown in 6 itraconazole not registered in 23 and unavailable in 23, while voriconazole is registered in only 12 countries and available only in 12, with flucytosine registered in three countries and available in only 1 country.\(^{26, 27}\)

The African continent has not previously developed a network of mycology experts whose goal is to provide a common platform for a comprehensive discussion and collaboration on fungal infections. The result of this lack of networked expertise has been uncoordinated activity of various scientists, clinicians, academicians and societies, sometimes duplicating efforts but more commonly being relatively ineffective, in terms of addressing the knowledge gaps in diagnosing and managing patients with fungal infections. The Africa Fund for Fungal Biodiversity and Mycotic Infections, initiated by G. Sybren de Hoog and Jacques F. Meis in 2014, organized and funded the inauguration of the Pan-African Medical Mycology Society (PAMMS) during a meeting entitled ‘Medical Mycology: The African Perspective’ on 25 Jan 2005 in Hartenbos (South Africa).\(^{28}\) In 2007 the second PAMMS meeting was held in Cape Town and the third in 2009 in Abuja, Nigeria. After this last meeting, 10 years ago, PAMMS fell away mostly due to the lack of leadership and possibly failure to include physicians. Recent renewed outreach efforts of ISHAM and also the European Confederation of Medical Mycology (ECMM) have aimed to increase involvement of African countries and experts in e.g. the “One World One Guideline” initiative\(^{29}\) and also the ECMM Academy.\(^{30}\) A network of mycology experts is required in Africa to provide a regional critical mass and common platform for clinical, laboratory, public education and collaboration on fungal infections. Expertise and data are required in each country.

The Pan-African Mycology Working Group (PAMWG) has been set up to organize and engage African leaders in the field of medical mycology in the African sub-region, linked to ISHAM. The aim of this Working Group for African clinicians, microbiologists, scientists, pharmacists and technicians is to provide a better interaction and synergy among regional
leaders in order to develop educational programs for capacity building to aid in the diagnosis and care of patients with fungal infections in Africa. The Working Group will also encourage country initiatives to develop clinical guidelines for the management of fungal infections and to support surveys and support the establishment of Mycology Reference Laboratories.

**Mission**

The PAMWG is an ISHAM working group composed of health-care professionals involved with mycology devoted to the understanding, diagnosis and management of invasive fungal infections, as well as the collation of fungal surveillance data for best outcomes of patients at risk of, or who are diagnosed with fungal infections in Africa.

**Objectives**

The ISHAM PAMWG aims to provide a platform for all the leaders in the field of mycology from multiple African countries in order to initiate epidemiological studies, regional guidelines, and educational programs to increase the capacity/ expertise of African specialists in the early detection and treatment of fungal infections. Additionally, we will be committed to advocacy activities to guide policy makers to provide the necessary support for the care of patients with fungal infections.

These activities will be fulfilled through the following activities;

- Education and training programs for health care workers involved in the care and evaluation of patients with fungal infections.
- South-south, and north-south collaborations and partnership.
- Organization of regional collaborative studies in the field of medical mycology.
- Encourage all PAMWG members to become members of ISHAM.
- Organize local meetings in African countries in collaboration with ISHAM.
- Assist PAMWG members to attend international congresses organized by ISHAM and ECMM.
- To ensure that fungal diseases in Africa are no longer neglected by bridging knowledge gaps.
Political will is essential in tackling the scourge of serious fungal infections in affected countries. Presently, there is no government resource allocation for surveillance, diagnostic facilities, outbreak response, epidemiological study and control of fungal infections, especially the life-threatening ones in Africa (apart from South Africa). Meeting the objectives listed above will generate the key data for advocacy needed to drive government commitment to allocate the resources required.

References


improve patient care and research worldwide: New leadership is about working together. Mycoses. 2018 Nov;61(11):885
<table>
<thead>
<tr>
<th>Country</th>
<th>2019 Population (million)</th>
<th>Total burden of serious fungal infection</th>
<th>Oesophageal candidiasis</th>
<th>Oral candidiasis</th>
<th>RVVC</th>
<th>Fungal keratitis</th>
<th>Tinea capitis</th>
<th>Serious fungal infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algeria</td>
<td>42.63</td>
<td>568,942</td>
<td>832</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,265</td>
</tr>
<tr>
<td>B/ Faso</td>
<td>20.28</td>
<td>1,360,28</td>
<td>7,450</td>
<td>24,300</td>
<td>179,00</td>
<td></td>
<td></td>
<td>1,132,781</td>
</tr>
<tr>
<td>Cameroon</td>
<td>25.45</td>
<td>1,126,33</td>
<td>43,300</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>721,000</td>
</tr>
<tr>
<td>Egypt</td>
<td>101.0</td>
<td>1,649,68</td>
<td>700</td>
<td>2,250</td>
<td>1,307,766</td>
<td></td>
<td></td>
<td>11,550</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>109.9</td>
<td>8,820,43</td>
<td>57,344</td>
<td>166,050</td>
<td>1,426,988</td>
<td></td>
<td></td>
<td>7,051,736</td>
</tr>
<tr>
<td>Ghana</td>
<td>30.06</td>
<td>1030563</td>
<td>18,292</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>598,840</td>
</tr>
<tr>
<td>Kenya</td>
<td>51.13</td>
<td>3,186,52</td>
<td>114,000</td>
<td>306,000</td>
<td>594,66</td>
<td></td>
<td></td>
<td>1,712,676</td>
</tr>
<tr>
<td>Malawi</td>
<td>19.68</td>
<td>1,338,52</td>
<td>73,000</td>
<td>216,000</td>
<td>326,96</td>
<td></td>
<td></td>
<td>670,900</td>
</tr>
<tr>
<td>Country</td>
<td>RVVC Rate (%)</td>
<td>Vulvovaginal Candidiasis Cases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mozambique</td>
<td>31.35</td>
<td>1,836,37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Namibia</td>
<td>2.63</td>
<td>60,456</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nigeria</td>
<td>200.0</td>
<td>17,983,5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Senegal</td>
<td>16.71</td>
<td>1,743,50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>58.01</td>
<td>4,047,13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanzania</td>
<td>60.79</td>
<td>1,422,20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>45.62</td>
<td>2,500,00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>815.37</td>
<td>47,643,9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RVVC – recurrent vulvovaginal candidiasis
Table 2: Description of some fungal infections which are unique to Africa

<table>
<thead>
<tr>
<th>Disease</th>
<th>Agent</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entomophthoromycosis</td>
<td><em>Conidiobolus coronatus</em>, <em>C.incongruous</em>, <em>Basidiobolus ranarum</em></td>
<td>Chronic subcutaneous zygomycosis of the face and limbs</td>
</tr>
<tr>
<td>Emergomycosis</td>
<td><em>Emergomyces africanus</em></td>
<td>...</td>
</tr>
<tr>
<td>African histoplasmosis</td>
<td><em>Histoplasma duboisi</em></td>
<td>Skin and subcutaneous nodules/ abscesses, and osteomyelitis</td>
</tr>
<tr>
<td>Favus</td>
<td><em>Trichosporon schoenlinii</em></td>
<td>Crusts of the scalp (scutulum) in children and few adolescents</td>
</tr>
</tbody>
</table>
Figure 1: Documented burden of fungal infections across Africa\textsuperscript{2}